Premium
Clinical Implementation of Pharmacogenetics: More than One Gene at a Time
Author(s) -
Johnson J A,
Klein T E,
Relling M V
Publication year - 2013
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2013.7
Subject(s) - pharmacogenetics , context (archaeology) , clinical pharmacology , cyp2c19 , cyp2d6 , medicine , pharmacology , personalized medicine , computational biology , gene , bioinformatics , biology , genetics , genotype , paleontology
Tricyclic antidepressant (TCA) clinical pharmacogenetic implementation guidelines for CYP2D6 and CYP2C19 genotypes highlight the importance of both genes. However, studies of the combined impact of the two genes are sparse, limiting the ability to make strong recommendations based on both genes. The warfarin pharmacogenetics literature highlights the strength of a multigenic approach for discovery and clinical implementation. For optimal impact and interpretation, investigators are encouraged to conduct studies in the context of previously well‐defined pharmacogenetics markers. Clinical Pharmacology & Therapeutics (2013); 93 5, 384–385. doi: 10.1038/clpt.2013.7